Literature DB >> 21703104

Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease.

Junichi Umemoto1, Naomi Tsurikisawa, Shinichi Nogi, Kanako Iwata, Chiyako Oshikata, Sayaka Tatsuno, Hidenori Tanimoto, Kiyoshi Sekiya, Takahiro Tsuburai, Hiroyuki Mitomi, Kazuo Akiyama.   

Abstract

Aspirin-induced asthma (AIA) is a severe and difficult-to-treat allergic disease in which acute asthma attacks are induced by nonsteroidal anti-inflammatory drugs. Patients with AIA rarely experience asthma attacks when taking celecoxib, a specific inhibitor of cyclooxygenase (COX) 2. A 33-year-old woman had a severe asthma attack with hypoxia and lost consciousness after oral provocation testing with 15 mg of aspirin and also with 50 mg of celecoxib. After 2 months of treatment with 10 mg/day of oral prednisolone, 1600 μg/day of inhaled fluticasone propionate, montelukast as a leukotriene receptor antagonist (LTRA), and long-term beta-agonist, we again challenged her with a provocation test with up to 200 mg of celecoxib; this time there were neither allergic symptoms nor decrease in forced expiratory volume in 1 second. Patients with severe or poorly controlled asthma may experience asthma attacks even if using selective COX-2 inhibitors. However, treatment with steroids and an LTRAs may inhibit asthma attacks induced by celecoxib.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703104     DOI: 10.2500/aap.2011.32.3413

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  5 in total

1.  Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity.

Authors:  Lily Li; Tanya Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2019-05-14

Review 2.  Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.

Authors:  Joshua M Levy; Luke Rudmik; Anju T Peters; Sarah K Wise; Brian W Rotenberg; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-08-02       Impact factor: 3.858

3.  Immunomodulatory treatments for aspirin exacerbated respiratory disease.

Authors:  Rachel G Moebus; Joseph K Han
Journal:  Am J Rhinol Allergy       Date:  2012 Mar-Apr       Impact factor: 2.467

Review 4.  Regulation of T helper cell subsets by cyclooxygenases and their metabolites.

Authors:  Hong Li; Matthew L Edin; Artiom Gruzdev; Jennifer Cheng; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-11-28       Impact factor: 3.072

5.  Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity.

Authors:  Yoon-Jeong Kim; Kyung-Hwan Lim; Mi-Young Kim; Eun-Jung Jo; Suh-Young Lee; Seung-Eun Lee; Min-Suk Yang; Woo-Jung Song; Hye-Ryun Kang; Heung-Woo Park; Yoon-Seok Chang; Sang-Heon Cho; Kyung-Up Min; Sae-Hoon Kim
Journal:  Allergy Asthma Immunol Res       Date:  2013-12-13       Impact factor: 5.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.